BioSpace News Archive

Envisagenics, a company developing therapeutics for RNA splicing errors that often lead to genetic disorders including cancer, announced today that it has entered into a research program agreement with the Lung Cancer Initiative (LCI) at Johnson & Johnson.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has entered into a sponsored research partnership agreement (“SRPA”) with the University of Wisconsin-Madison to evaluate novel formulations and drug delivery technology focused on psilocybin-based pharmaceuticals.

Colorado BioScience Association (CBSA) today welcomed new officers and members to its board of directors, including new board chair, Bob Reddy, and new board vice chair, Dr. Kathleen (Kiki) Traylor.

In a continued effort to help fight the COVID-19 crisis, Eurofins Technologies announces the CE-IVD marking of a first range of testing kits for serology-based antibody detection by ELISA of patients who have been exposed to COVID-19

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies that are specific for ipilimumab (Yervoy) and the ipilimumab/CTLA-4 drug-target complex

Regenstrief Institute and partners have developed a data dashboard to support COVID-19 tracking and response in the state of Indiana

ADOC the “Company”and “Adocia”), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, will hold its annual shareholders’ meeting (“AGM”) on May 28th, 2020, at 10 am at the Company’s headquarter, 115 avenue Lacassagne, 69003, Lyon, France.

A few months ago, Pac Team Group was building showcases for the world’s most renowned brands.

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020 its financial results for the first quarter ending March 31st, 2020.

Cellphire, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire’s next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients.